GlassScriptPhysician profile
Amy Jo Renfro
NPI 1467935163
$2,151.49
in general payments reported to CMS, 2019-2025
21 companies · $580 in 2025
The $580 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.99 · 2022: $36.24 · 2023: $582 · 2024: $918 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,040 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,039.82 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $451.35 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $314.24 | 2023-2025 | Verquvo, Belsomra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $185.35 | 2023-2025 | Lifevest |
| Amgen INC. | $171.36 | 2023-2025 | Repatha, Repatha |
| Irhythm Technologies, INC. | $158.69 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $125.18 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $91.55 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.03 | 2023-2024 | Jardiance |
| Esperion Therapeutics, INC. | $68.72 | 2024-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $65.23 | 2023-2024 | Camzyos |
| Abiomed | $64.06 | 2025 | |
| Astellas Pharma US INC | $57.06 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $52.38 | 2023 | Optimizer |
| Alnylam Pharmaceuticals INC. | $49.31 | 2023-2025 | Onpattro |
| Surmodics, INC. | $46.61 | 2025 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy, Pounce Thrombectomy System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $46.10 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $40.66 | 2025 | Farxiga |
| Philips North America LLC | $24.57 | 2023 | |
| Boston Scientific Corporation | $23.53 | 2025 | Watchman Flx |
| Scpharmaceuticals INC. | $22.53 | 2024 | |
| Glaxosmithkline, LLC. | $18.98 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Renfro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.